Wedbush reiterated their outperform rating on shares of Unity Biotechnology (NASDAQ:UBX – Get Rating) in a research note released on Thursday morning, Benzinga reports. The brokerage currently has a $35.00 target price on the stock.
A number of other research analysts also recently issued reports on the company. Mizuho cut their price objective on Unity Biotechnology from $80.00 to $12.00 and set a buy rating for the company in a research note on Wednesday, November 16th. HC Wainwright reiterated a buy rating and set a $10.00 price objective on shares of Unity Biotechnology in a research note on Wednesday, February 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $34.25.
Unity Biotechnology Trading Down 6.7 %
NASDAQ UBX opened at $3.78 on Thursday. Unity Biotechnology has a 52 week low of $2.09 and a 52 week high of $18.50. The company has a quick ratio of 6.12, a current ratio of 4.92 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $4.31 and a 200-day moving average price of $3.86.
Institutional Inflows and Outflows
About Unity Biotechnology
Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on Unity Biotechnology (UBX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.